* Procept Biorobotics Corp PRCT.OQ PRCT.O is expected
to show
a rise in quarterly revenue when it reports results on February
27 for the period ending December 31 2023
* The San Jose California-based company is expected to
report a
76.9% increase in revenue to $42.062 million from $23.78 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Procept Biorobotics Corp
is
for a loss of 44 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Procept
Biorobotics Corp is $50.00, above its last closing price
of $48.83.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.51 -0.51 -0.51 Met 0.9
Jun. 30 2023 -0.57 -0.57 -0.56 Beat 2
Mar. 31 2023 -0.58 -0.58 -0.63 Missed -8.4
Dec. 31 2022 -0.55 -0.54 -0.56 Missed -2.9
Sep. -0.48 -0.48 -0.51 Missed -6
30 2022
Jun. 30 2022 -0.48 -0.48 -0.43 Beat 10.8
Mar. 31 2022 -0.48 -0.47 -0.39 Beat 17.5
Dec. 31 2021 -0.41 -0.39 -0.42 Missed -7.7
This summary was machine generated February 24 at 03:05 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)